Evidence mapPaperPMID 41998536Full record

SynthesisBMC geriatrics2026

The views of healthcare professionals and family members on deprescribing preventive medication in people living with dementia: a qualitative systematic review.

Clare Bates, Nikolaos Efstathiou, Claire Sutton, Nesrein Hamed, Ian Maidment

Abstract readSystematic Review
In one paragraph

Synthesis in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Clare BatesPharmacy School, Aston University, Birmingham, England. clare.bates@nihr.ac.uk.
Nikolaos EfstathiouSchool of Nursing and Midwifery, University of Birmingham, Birmingham, England.
Claire SuttonSchool of Nursing and Midwifery, University of Birmingham, Birmingham, England.
Nesrein HamedPharmacy School, Aston University, Birmingham, England.
Ian MaidmentPharmacy School, Aston University, Birmingham, England.

Funding

NIHR Academy NIHR304995
6 · The paper itself

Abstract

backgroundPeople living with dementia often continue to take preventive medication until the end of their lives, largely with the aim of prolonging life. However, at the later stages of dementia, a palliative-only, symptom-controlling approach, may be more appropriate. Also, the efficacy of preventive medications in older people is often unclear and the side effects may have a negative impact on quality of life, yet these medicines are often not deprescribed.

aimTo synthesise qualitative evidence of healthcare professionals’ and family members’ views on deprescribing preventive medication for people living with dementia.

methodsThe systematic review was conducted using the principles for systematic reviews of qualitative evidence provided by Cochrane. In May 2025, keywords were searched for in Embase, Health Management Information Consortium, MEDLINE, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, PubMed, Open Access Theses and Dissertations, Web of Science, ProQuest, Cochrane Central Library and Google Scholar to identify suitable studies from pre-defined eligibility criteria. The Critical Appraisal Skills Programme was used for quality appraisal and Thomas and Harden’s qualitative thematic synthesis for synthesising findings.

resultsEighteen studies were included. Five themes were identified: the decision-makers, reactive reasons to deprescribe, barriers and facilitators to proactive deprescribing, difficulties for family members and the timing of deprescribing decisions. Guidance is often unclear for this complex group, but guidance is unlikely to cover every individuals’ unique situation. Ideally, in practice, deprescribing should occur before someone gets to a stage when they can no longer communicate side effects and this may instigate more deprescribing discussions. To assist deprescribing, recording why a medication was started on the prescription could make it clearer whether to discontinue it at a later stage.

conclusionDeprescribing conversations are difficult for both healthcare professionals and family members. Future research could explore the role of advance care planning for deprescribing preventive medications, before someone is diagnosed with dementia, so decision-makers are aware of what the person would have wanted. This may make deprescribing less time-consuming, provide guidance and reduce the burden for the decision-makers.

trial registrationPROSPERO CRD42023476394 (October 2023).

Indexed as

Attitude of Health PersonnelDementiaDeprescriptionsFamilyHealth PersonnelHumansQualitative ResearchAdvance care planningAdvance decision to refuse treatmentDecision-makingDementiaDeprescribingLife-prolongingLife-sustainingMental capacityPreventive medicationQualitative systematic review

Identifiers

PMID41998536
PMCPMC13220616

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.